Ayala Pharmaceuticals, Inc. (AYLA)

Balance Sheet (Annual)

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2021	2020	2019	2018
Cash & Equivalents	36.98	42.03	16.73	26.1
Short-Term Investments	0.12	0.09	0.08	0.17
Cash & Cash Equivalents	37.1	42.12	16.81	26.26
Cash Growth	-11.90%	150.57%	-36.00%	-
Receivables	0	0.68	0.47	0
Other Current Assets	2.64	1.44	0.42	0.59
Total Current Assets	39.74	44.24	17.69	26.85
Property, Plant & Equipment	1.12	1.28	1.42	0.24
Other Long-Term Assets	0.27	0.31	0.94	0.03
Total Long-Term Assets	1.39	1.59	2.36	0.27
Total Assets	41.13	45.83	20.05	27.13
Accounts Payable	6.47	6.88	5.3	2.77
Total Current Liabilities	6.47	6.88	5.3	2.77
Other Long-Term Liabilities	0.5	0.55	53.67	46.21
Total Long-Term Liabilities	0.5	0.55	53.67	46.21
Total Liabilities	6.97	7.43	58.97	48.98
Common Stock	145.3	109.29	1.82	1.09
Retained Earnings	-111.14	-70.89	-40.74	-22.95
Shareholders' Equity	34.16	38.4	-38.92	-21.86
Total Liabilities and Equity	41.13	45.83	20.05	27.13
Net Cash / Debt	37.1	42.12	16.81	26.26
Net Cash / Debt Growth	-11.90%	150.57%	-36.00%	-
Net Cash Per Share	2.58	4.27	3.38	5.32
Working Capital	33.27	37.36	12.39	24.08
Book Value Per Share	2.37	3.89	-7.82	-4.43

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).